Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02628067
Title	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Acronym	MK-3475-158/KEYNOTE-158
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	bile duct carcinoma lung small cell carcinoma thyroid gland carcinoma Advanced Solid Tumor malignant mesothelioma cholangiocarcinoma salivary gland cancer endometrial carcinoma gallbladder adenocarcinoma neuroendocrine tumor cervix carcinoma vulva carcinoma anal canal carcinoma
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NOR \| NLD \| ITA \| ISR \| FRA \| ESP \| DNK \| DEU \| BRA \| AUS